



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:



Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com

  @G2Gconsulting

Updated Monthly

October 9, 2025

Prepared for:





TABLE OF CONTENTS

New Opportunities

Aging.....	2
Artificial Intelligence & Machine Learning	3
Biomedical Research.....	3
Biotechnology and Biomanufacturing.....	5
Cancer	5
Cardiovascular and Pulmonary Health.....	6
Combat Casualty Care.....	8
Communication Disorders	8
Complementary and Integrative Health	8
Digestive Diseases.....	9
Down Syndrome	9
General Medical Sciences	11
Genomics	11
Health IT & Data	12
Hematology.....	12
HIV/AIDS	12
Immunology & Infectious Disease	12
Maternal and Pediatric Health	13
Medical Countermeasures.....	14
Mental Health.....	14
Microgravity Research.....	15
Nursing Research	15
Precision Medicine	15

GBG Report

Updated Monthly

October 9, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

Rare Diseases	16
Reproductive Health.....	16
Small Business Development	16
Substance Use Disorder	17
Therapeutics.....	18
Toxic Exposures	19
Urologic Research.....	19

Recurring Opportunities

Advanced Research Projects Agency for Health.....	20
Air Force	21
Army.....	22
BARDA	24
DARPA	24
Defense Threat Reduction Agency	25
Department of Energy	26
National Science Foundation	26
Navy	26
Office of the Undersecretary of Defense	27
Patient-Centered Outcomes Research Institute	27

GBG Acronyms	29
---------------------------	-----------



October 16, 2025 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, NMBio, Ohio Life Sciences, South Dakota Biotech, VaBio, or WVBio – your membership gets you access to the [private consultation meeting](#).

Government Shutdown – G2G is following the events closely, and keeping our clients updated. See the [latest update on the G2G website](#), and [subscribe to our newsletter](#) to ensure you receive the latest news.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (3)		
1.	Forecast: Discovery of in vivo Chemical Probes for the Nervous System (NIH) PAR-26-095	This NOFO will support investigators who have an interest and the capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. The purpose is to stimulate research in: Discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the mission(s) of NEI, NIDA, NIMH, and/or NIA, and Discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. https://www.grants.gov/search-results-detail/360676	TBD	Estimated post date: 2/26/26 Estimated proposal date: 6/5/26
2.	Forecast: Palliative Care Research Across the Lifespan: Leveraging the Palliative Care Consortium (NIH/NIA) PAR-26-097	This NOFO will invite applications proposing research on palliative care across the lifespan for persons with serious illnesses and/or their caregivers, including projects focused on characterizing or mitigating disparities in palliative care access, quality, and use. https://www.grants.gov/search-results-detail/360675	TBD	Estimated post date: 3/1/26 Estimated proposal date: 6/5/26
3.	Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional) (NIH/NIA) RFA-AG-26-025	The goal of the OAIC program is to establish centers of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-025.html	Up to \$925,000 per year, for up to 5 years	Proposal: 10/20/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (3)		
4.	Artificial Intelligence and Technology Collaboratory (P30 Clinical Trial Optional/U24 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-26-006 (P30) RFA-AG-26-007 (U24)	The AITC program promotes the development and implementation of AI approaches and technology through research projects for aging and AD/ADRD research. All applications should propose strategies for addressing challenges surrounding AI and technology development and implementation, and to employ, when possible, best practices established in the fields of aging and AD/ADRD. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-006.html (P30) https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-007.html (U24)	Up to \$4 million per year, for up to 5 years (P30) Up to \$1.9 million per year, for up to 5 years (U24)	Proposal: 10/15/25
5.	Pitching Critical Assessment for Therapeutic Protein Design (CAT-PD) QuickFire Challenge (J&J)	Innovators around the world are invited to submit their novel technologies and/or techniques with sufficient detail to determine the potential to generate de novo designed sequences against a target of interest. Specific area of interest: AI/ML models with the ability to predict and/or generate antigen-antibody binding interactions against a targeted epitope. https://jnjinnoation.com/innovation-challenges/Pitching-Critical-Assessment-for-Therapeutic-Protein-Design-(CAT-PD)-QuickFire-Challenge	Opportunity to pitch at conference in January 2026	Proposal: 11/21/25
		BIOMEDICAL RESEARCH (8)		
6.	Smart-Red Blood Cells (Smart-RBC) (DoD/DARPA) DARPA-SN-25-108	The DARPA Smart-RBC program aims to engineer red blood cells to contain novel biological features that can safely and reliably modify human physiology. Specifically, the Smart-RBC program seeks to revolutionize blood products by creating “smart red blood cells” (SRBCs). https://sam.gov/opp/81a3df4c381b43c58b2e9b83f56b747d/view	TBD	Proposer's Day registration: 10/14/25 Proposer's Day: 10/20/25
7.	Forecast: NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional) (NIH) PA-26-002	This NOFO will support international research collaborations. This opportunity specifically implements an award structure of prime domestic awards with independent foreign awards that are linked to the prime. This structure provides NIH with oversight capacity for international collaborations, and allows NIH to track international funding. https://www.grants.gov/search-results-detail/360581	TBD	Estimated post date: 11/25/25 Estimated proposal date: 1/25/26
8.	Forecast: Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) (NIH) PAR-25-458	This NOFO will encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. https://www.grants.gov/search-results-detail/360543	TBD	Estimated post date: 2/5/26 Estimated proposal date: 12/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
9.	Forecast: Interdisciplinary Research Networks to Advance Biomedical Research on Resilience and Health Optimization (NIH/NCCIH) RFA-AT-26-001	This NOFO aims to support interdisciplinary research networks to advance biomedical research on resilience. https://www.grants.gov/search-results-detail/360645	Total funding of \$1.5 million	Estimated post date: 1/5/26 Estimated proposal date: 5/25/26
10.	Forecast: NIBIB Technology Development Networks (NIH/NIBIB) RFA-EB-26-001	These Coordinating Centers are designed to bring scientific and engineering communities together to solve translational problems. The Coordinating Centers will be responsible for enhancing integration between components of the Network by facilitating opportunities for collaborations across technology development projects. https://www.grants.gov/search-results-detail/360629	Up to \$1 million	Estimated post date: 5/1/26 Estimated proposal date: 8/1/26
11.	Forecast: Screening for Conditions by Electronic Nose Technology (SCENT III) (Clinical Trial Not Allowed) (NIH/NCATS) RFA-TR-26-001	This NOFO seeks to develop electronic nose technologies that mimic the olfactory system, leading to a robust diagnostic platform subject to validation and regulatory approval. Under this iteration of the NOFO, improved sensing, detection, and analytical technologies will be developed for integration into tools for disease diagnosis and monitoring in everyday settings. These novel technologies will complement traditional blood analysis and other invasive, expensive, and highly technical procedures to monitor the onset, progression, and resolution of disease. https://www.grants.gov/search-results-detail/360672	TBD	Estimated post date: 2/5/26 Estimated proposal date: 6/5/26
12.	NIH Common Fund Replication Prize (NIH Common Fund)	This prize seeks to collect ideas and strategies to make important areas of biomedical research more replicable. Submissions can address one or both of two tracks: (1) Replication Ideas: Submit ideas on research questions that can benefit most from replication; (2) Replication Exemplars: Submit a report on a creative and successful way the team has integrated replication into their standard practice. Entrants are permitted to submit one entry per track. https://www.challenge.gov/?challenge=replication-prize	Total funding of \$850,000	Proposal: 12/19/25
13.	Complement-ARIE NAMs Reduction to Practice Challenge (NASA)	This challenge invites innovative combinatorial NAMs solutions from multidisciplinary teams who can successfully demonstrate implementation of their human-based solution in a practical and usable form within a 3-year period. Priority areas include: Chronicity, Neurobiological Models; Personalized Medicine; Cross-Disease Pathogenesis; Toxicology and Safety; and Human Health Protection. https://www.herox.com/Complement-ARIE-RTP	Up to \$1.43 million, over 3 years	Proposal: 3/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOTECHNOLOGY AND BIOMANUFACTURING (2)		
14.	Antibody (Ab) Advanced Manufacturing Capability Improvement: Smart Technologies (BARDA/BioMaP) 25-11-Smart Ab	BARDA is seeking to improve (enhance) the speed and efficiency of antibody production. This effort is directed at developing and implementing FDA Advanced Manufacturing goals within the antibody manufacturing environment. Innovations of most interest are those that rapidly scale manufacturing capabilities (scalability), create a distributed network of manufacturing sites (portability), improve cost-efficiency of manufacturing processes, and create new tools that can address drug shortages in support of the emergency preparedness and response mission of BARDA. https://www.biomap-consortium.org/rpp-25-11-smart-ab/	Total funding of \$13.2 million	Enhanced White Paper: 10/22/25
15.	Genetic Medicines And Individualized Manufacturing For Everyone (GIVE) Program (ARPA-H) ARPA-H-SOL-25-129	GIVE aims to accelerate biomanufacturing equipment and process innovation, digital transformation, next generation therapies, and commercial adoption all at once. GIVE seeks to harness human-machine collaboration, eliminate scale-up costs, and drive toward a fundamentally different future state – a state where biomanufacturing is localized, accessible, and individualized. https://sam.gov/workspace/contract/opp/6a5b59b7c5034510a74c38789839bb4a/view https://sam.gov/workspace/contract/opp/000dca8baf6d44c39c90c47d62c47f48/view	Dependent upon proposal and award mechanism	Proposer's Day: 11/13/25 Solution Summary: 12/19/25 Proposal: 2/27/26
		CANCER (3)		
16.	Forecast: Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required) (NIH/NCI) PAR-26-064	This NOFO will support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. https://www.grants.gov/search-results-detail/360541	Total funding of \$25 million	Estimated post date: 10/31/25 Estimated proposal date: 1/25/27
17.	Forecast: Glioblastoma Therapeutics Network (GTN; U19 Clinical Trial Required) (NIH/NCI) RFA-CA-25-033	This NOFO will solicit applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms. https://www.grants.gov/search-results-detail/360606	TBD	Estimated post date: 11/28/25 Estimated proposal date: 5/27/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
18.	Forecast: Partnering Research and Community Organizations for Comparative Clinical Effectiveness Research Across the Cancer Care Continuum PCORI Funding Announcement (The Cancer Partner PFA) -- Cycle 1 2026 (PCORI)	This PFA invites CER applications led by researcher-community partnerships that may focus on a range of research questions and decisional dilemmas relevant to the participating communities that address variations in care and outcomes across the cancer continuum. PCORI is particularly interested in submissions that address the following Special Areas of Emphasis: Addressing barriers to recommended cancer screening and timely follow-up in the general population and among individuals at high risk of cancer; Improving the delivery of patient-centered, evidence-based care during cancer treatment; and Addressing the post-treatment, follow-up care needs of cancer survivors. https://www.pcori.org/funding-opportunities/announcement/cancer-partner-pfa-cycle-1-2026	Up to \$13 million, for up to 6 years	System opens: 12/2/25 Letter of intent: 1/6/26 Proposal: 5/5/26
		CARDIOVASCULAR AND PULMONARY HEALTH (2)		
19.	Viral Infections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional) and Data Analytics and Coordinating Center (DACC)(U24 Clinical Trial Optional) (NIH/NHLBI) RFA-HL-26-006 (UG3/UH3) RFA-HL-26-008 (U24)	The VINYL Consortium seeks to understand the heterogeneity and underlying mechanisms of viral lower respiratory tract infections (LRTI) in hospitalized young children between 0–2 years of age, and their impact on pulmonary outcomes at pre-school age. This will be accomplished through a prospective, longitudinal observational cohort study performing deep phenotyping at the time of enrollment (upon hospitalization) with common data and biospecimen collection from 1500 young children with respiratory viral infections and one or more of the following diagnoses: bronchiolitis, pneumonia and pediatric acute respiratory distress syndrome (PARDS). Each CC should consist of one main site and 1-3 optional sub-sites, and plan on enrolling participants in a Consortium-wide longitudinal cohort study with deep phenotyping and characterization at enrollment during hospitalization. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-006.html (UG3/UH3) https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-008.html (U24)	Up to \$1.64 million, for up to 1 year (UG3) Up to \$31.1 million, for up to 6 years (UH3) Up to \$4.6 million, for up to 7 years (U24)	Proposal: 11/10/25
20.	Forecast: Global Brain and Nervous System Disorders Research Across the Lifespan - Exploratory Grants (NIH/Fogarty) PAR-25-456	Awards will catalyze and strengthen collaborative research on the brain and nervous system that leverages the unique scientific contexts of low- and middle-income countries (LMICs) not readily present in the United States and, subsequently, optimizes our potential to address health needs in the U.S. and globally. Research on the full spectrum of neuro-health across the lifespan is encouraged - including neurological, neuromuscular, sensory, neuropsychiatric, neuroinfectious, cognitive, behavioral, and neurodevelopmental disease - and encompassing basic, clinical, translational, and implementation research approaches. https://www.grants.gov/search-results-detail/360660	TBD	Estimated post date: 12/23/25 Estimated proposal date: 2/24/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH (5)		
21.	BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed) (NIH) RFA-DA-27-004	This NOFO seeks applications to develop theories, models and methods (TMM) as tools that will advance a quantitative and predictive understanding of brain function across multiple scales, including behavior. Priority will be given to projects that develop novel capabilities for analyzing, integrating, and interpreting the large-scale, complex data emerging from the BRAIN Initiative and related efforts, which includes cell-type specific physiological, anatomical, connectivity, and behavioral data. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-27-004.html	Up to \$350,000 per year, for 3 years	Multiple deadlines; NOFO open through 11/8/28
22.	Forecast: Autism Centers of Excellence R01 and P50 (NIH) RFA-HD-27-001 RFA-HD-27-002	These NOFOs will solicit applications for research that will build on the progress and momentum of the past 23 years of ACE research and that takes advantage of cutting-edge technologies and methods. https://www.grants.gov/search-results-detail/360643 https://www.grants.gov/search-results-detail/360644	Total funding of \$20 million	Estimated post date: 7/1/26 Estimated proposal date: 11/2/26
23.	Forecast: Investigate Novel Therapeutic Interventions and Testing Strategies for Neurological Disorders Including to Treat, Modify and Prevent the Development of Epilepsy (U24 Clinical Trial Not Allowed) (NIH/NINDS) RFA-NS-26-002	This NOFO will solicit applications to investigate novel therapeutic interventions and testing strategies for neurological disorders including to treat, modify, and prevent epilepsy. This research should include various intervention modalities and testing strategies. https://www.grants.gov/search-results-detail/360649	Up to \$4 million	Estimated post date: 12/19/25 Estimated proposal date: 2/20/26
24.	Forecast: Research Program Award (R35 Clinical Trial Optional) (NIH/NINDS) RFA-NS-26-006	This Research Program Award affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor students and postdoctorates, which support and align with the mission of NINDS. https://www.grants.gov/search-results-detail/360648	Up to \$750,000	Estimated post date: 4/15/26 Estimated proposal date: 7/15/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COMBAT CASUALTY CARE (2)		
25.	Medics Autonomously Stopping Hemorrhage (MASH) (DoD/DARPA) DARPA-PS-25-34	The MASH Program aims to develop capabilities which do not require a surgeon and can occur in forward medical facilities to stabilize NCTH by autonomously finding and stopping bleeding in the torso. MASH will focus on the key problem: finding and stabilizing the bleed inside the human torso via external, laparoscopic, endovascular or hybrid approaches utilizing novel autonomy and signal processing and existing sensor suites, surgical or endovascular maneuvers, and robotic platforms. https://sam.gov/workspace/contract/opp/6d826add665048888c9317b598e61991/view	Total funding of \$32.4 million	Abstract: 10/15/25 Proposal: 11/25/25
26.	Advanced Medical Monitor (MTEC) MTEC-25-09-AMM	The RPP is focused on developing Advanced Medical Monitor (AMM) Family of systems (FoS) components, including the Next Generation Medical Monitor (NGMM) and the Expeditionary Medical Monitor (EMM), which continuously track vital signs and other relevant data. Both devices must be designed for expeditionary medical use and easy to maintain. The desired prototypes, by their final design, will need to be capable of advanced noninvasive physiological monitoring to provide actionable information for enhanced military patient triage, to reduce cognitive workload, to inform treatment and evacuation priorities, as well as monitor vital signs of patients under medical care. https://mtec-sc.org/solicitations/25-09-amm	Up to \$4 million, for up to 2 years	White paper: 10/24/25
		COMMUNICATION DISORDERS (1)		
27.	NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional) (NIH/NIDCD) PAR-25-445	This NOFO invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human sensory and communication disorders. https://grants.nih.gov/grants/guide/pa-files/PAR-25-445.html	Up to \$1.5 million per year, for up to 5 years	Multiple deadlines; NOFO open through 6/2/28
		COMPLEMENTARY AND INTEGRATIVE HEALTH (1)		
28.	Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required) (NIH/NCCIH) PAR-25-449	This NOFO solicits applications for research on how mind and body interventions through psychological and/or physical practices (e.g., mindfulness meditation, yoga, acupuncture, massage, and other brain- and/or body-based interventions) impact mechanisms of emotional well-being (EWB) and their associations with whole person health (WPH), consistent with the NIH priority to address the health needs of the American people and improve their well-being. https://grants.nih.gov/grants/guide/pa-files/PAR-25-449.html	Up to \$475,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 6/7/28



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DIGESTIVE DISEASES (4)		
29.	Forecast: The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genomic Research Centers and Data Coordinating Center (NIH/NIDDK) RFA-DK-27-116 RFA-DK-27-124	The IBDGC will leverage patient cohorts, biospecimens and advances in data science to characterize the interactions of genetic, clinical and environmental factors in disease development and progression, and to develop new predictors of disease outcomes, with the goal of improving medical management and advancing precision medicine for IBD patients. https://www.grants.gov/search-results-detail/360621 https://www.grants.gov/search-results-detail/360622	Total funding of \$8 million	Estimated post date: 8/1/26 Estimated proposal date: 11/1/26
30.	Forecast: The NIDDK Disorders of Gastrointestinal Interoception Consortium Clinical Centers (DGIC) (NIH/NIDDK) RFA-DK-27-117 RFA-DK-27-118	Interoception is the ability of the nervous system to sense, interpret and coordinate signals from various bodily systems including the GI tract. Many functional GI disorders are associated with a spectrum of overlapping symptoms including nausea, vomiting, and altered bowel habits all of which involve altered interoceptive signaling. This initiative would broaden the scope beyond gastroparesis to include other adult and pediatric GI conditions associated with impaired interoceptive processing to form a Disorders of Gastrointestinal Interoception Consortium (DGIC). https://www.grants.gov/search-results-detail/360625 https://www.grants.gov/search-results-detail/360623	Total funding of \$4.5 million	Estimated post date: 8/1/26 Estimated proposal date: 11/1/26
		DOWN SYNDROME (3)		
31.	Forecast: INCLUDE Project: Exploratory/Developmental Research Awards, Transformative Research Awards; and Clinical Trials Phased Awards for Down syndrome (R21/R01 Clinical Trial Not Allowed)/(R61/R33 Clinical Trial Required) (NIH) RFA-OD-25-019 (R21) RFA-OD-25-020 (R01) RFA-OD-25-021 (R61/R33)	The INCLUDE Project seeks to improve health and quality-of-life for individuals with Down syndrome. These NOFOs support new exploratory and developmental research projects that address critical needs; groundbreaking, exceptionally innovative, original, and/or unconventional research that has the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies; and development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome. https://www.grants.gov/search-results-detail/360653 (R21) https://www.grants.gov/search-results-detail/360654 (R01) https://www.grants.gov/search-results-detail/360655 (R61/R33)	Up to \$275,000, for up to 2 years (R21) Up to \$500,000 per year, for up to 5 years (R01) Total funding of \$3 million, for up to 5 years (R61/R33)	Estimated post date: 12/19/25 Estimated proposal date: 2/19/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE & METABOLIC DISEASE (7)		
32.	Forecast: Kidney Precision Medicine Project Recruitment Sites, Tissue Interrogation Sites, and Central Hub (U01/U24 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-26-301 (U01) RFA-DK-26-302 (U01) RFA-DK-26-303 (U24)	The Kidney Tissue Atlas Coordinating Center (KTACC) will collaborate with the Central Hub (CH), Recruitment Sites (RS), Tissue Interrogation Sites (TIS), and to obtain and evaluate kidney biopsies from participants with acute kidney injury (AKI) or chronic kidney disease (CKD), create a Kidney Tissue Atlas, define disease subgroups, and identify critical cells, interstitial components, pathways, and targets for novel therapies. https://www.grants.gov/search-results-detail/360549 (U01) https://www.grants.gov/search-results-detail/360550 (U01) https://www.grants.gov/search-results-detail/360552 (U24)	Total funding of \$15 million for all three NOFOs	Estimated post date: 7/5/26 Estimated proposal date: 10/5/26
33.	Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required) (NIH/NIDDK) RFA-DK-26-315	This NOFO invites applications designed to examine the efficacy of digital health technology approaches to the management of diabetes. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-315.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 10/6/26
34.	Forecast: Collaborative Awards to Support Microphysiological System Pilot Studies in Type 2 Diabetes Research (NIH/NIDDK) RFA-DK-27-102	This NOFO will solicit applications for research on microphysiological systems (MPSs) to model type 2 diabetes. Advances in biomaterials, microfluidics, and tissue engineering have resulted in MPSs that allow for greater control of three-dimensional cell cultures containing multiple cell types and constituting more physiological tissue organization. The current initiative will support small pilot studies to conceptualize aspects of T2D biology for modeling with MPSs, to support feasibility studies, and to generate preliminary data. https://www.grants.gov/search-results-detail/360659	Total funding of \$1 million	Estimated post date: 4/1/26 Estimated proposal date: 7/5/26
35.	Forecast: Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed) (NIH/NIDDK) RFA-DK-27-106	This NOFO will solicit applications for research on collecting and analyzing data from clinical trials involving isolated human islets as a treatment for diabetes. This data will be used by research community for publications and presentations and to help design future clinical trials. https://www.grants.gov/search-results-detail/360637	Total funding of \$700,000	Estimated post date: 7/1/26 Estimated proposal date: 10/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE & METABOLIC DISEASE		
36.	Forecast: Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (NIH/NIDDK) RFA-DK-27-108	This NOFO will solicit applications for discovery and mechanistic research to advance the understanding of cardiovascular disease in type 1 diabetes through a continuation of the CARE-T1D consortium. https://www.grants.gov/search-results-detail/360626	Total funding of \$4.5 million	Estimated post date: 4/1/26 Estimated proposal date: 7/1/26
		GENERAL MEDICAL SCIENCES (1)		
37.	Forecast: Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (ESI) (NIH/NIGMS) PAR-26-032	MIRA provides support for research in an investigator's laboratory that falls within the mission of NIGMS through a single grant award. It provides investigators with greater funding stability and scientific flexibility, enabling researchers to take on more ambitious and innovative studies, enhancing scientific productivity and the chances for important breakthroughs. https://www.grants.gov/search-results-detail/360593	TBD	Estimated post date: 3/1/26 Estimated proposal date: 10/5/26
		GENOMICS (3)		
38.	NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed) (NIH/NHLBI) PAR-25-447	The overall goal is to move from simply cataloging genetic associations to understanding how genetic factors contribute to HLBS diseases at the molecular and cellular levels. This transformation will help move TOPMed from genetic Map to Mechanism with potential applications of AI and ML tool sets where possible, enabling functional genomics research that will accelerate mechanistic personalized medicine. https://grants.nih.gov/grants/guide/pa-files/PAR-25-447.html	Resource support only (X01)	Multiple deadlines; NOFO open through 5/8/28
39.	Forecast: Centers of Excellence in Genomic Science (CEGS) (NIH/NHGRI) PAR-26-036	The purpose of the CEGS program is to bring together interdisciplinary teams of investigators to form tightly focused, well-integrated projects that address challenging biomedical questions from a genomics perspective. CEGS are expected to develop highly innovative novel concepts, methods, approaches, tools, and technologies to address these questions and achieve a transformative advance not likely developed by standard R01s or other projects over the same timeframe. https://www.grants.gov/search-results-detail/360642	Total funding of \$5 million	Estimated post date: 3/25/26 Estimated proposal date: 6/24/26
40.	Forecast: Toolkits for Dissemination of Genomic Technologies (NIH/NHGRI) PAR-26-037	The Toolkits for Dissemination of Genomic Technologies initiative will create a pathway to lower the barrier to technology adoption by supporting the dissemination efforts of tool and technology developers in the form of an integrated toolkit containing the necessary components and information required to implement the technology. https://www.grants.gov/search-results-detail/360641	Up to \$50,000	Estimated post date: 3/25/26 Estimated proposal date: 6/24/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA (1)		
41.	Forecast: Data Sharing for Demographic Research Infrastructure Program (NIH/NICHD) RFA-HD-27-005	This NOFO will continue supporting a repository for datasets produced through support from the Population Dynamics Branch (PDB) and other components of NICHD's Division of Extramural Research. DSDR is widely used by NICHD grantees; complies with NIH data sharing requirements; is listed in the NLM Open Domain-Specific Data Sharing Repositories; and holds more than 3,000 datasets containing over 1.5 million variables. https://www.grants.gov/search-results-detail/360582	Up to \$600,000	Estimated post date: 3/20/26 Estimated proposal date: 7/22/26
		HEMATOLOGY (1)		
42.	Forecast: Cooperative Centers of Excellence in Hematology (CCEHs) (NIH/NIDDK) RFA-DK-27-127	The Cooperative Centers of Excellence in Hematology (CCEHs) are a national network of cores that provide state-of-the-art resources and services, expertise, enrichment activities, and small pilot and feasibility (P&F) funding to support and enhance the nonmalignant hematology research community and the quality of its science. The renewal of the CCEH program with enhanced strategies will improve the transparency, accountability, shareability, and overall excellence of the program. https://www.grants.gov/search-results-detail/360674	Total funding of \$3.745 million	Estimated post date: 4/1/26 Estimated proposal date: 7/10/26
		HIV/AIDS (1)		
43.	Forecast: Consortia for Structure-based Immunogen Design for HIV (CSID-HIV) (NIH/NIAID) RFA-AI-27-020	This NOFO will support research to support structure-based immunogen design to advance the development and selection of HIV immunogens that induce broadly neutralizing antibody (bNAb) responses. These immunogens will then be advanced into clinical testing. Consortium research should address critical immunogen design roadblocks in discovering and developing safe and effective HIV bNAbs and bNAb responses that can be used as therapeutics, as well as guide vaccine development that could be used for both HIV treatment and prevention. https://www.grants.gov/search-results-detail/360591	TBD	Estimated post date: 2/15/26 Estimated proposal date: 4/14/26
		IMMUNOLOGY & INFECTIOUS DISEASE (4)		
44.	Forecast: Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases (CDC/NCEZID) CDC-RFA-CK-26-0107	This NOFO will support clinicians, healthcare professionals, healthcare systems, institutions, and organizations directly involved in patient care, public health, and infectious disease control across the United States. By strengthening the capacity of these key stakeholders, the program will enable more effective frontline engagement, facilitate the implementation of timely public health responses, and generate expert insights to inform and improve public health guidance and practice. https://www.grants.gov/search-results-detail/360691	Up to \$30 million	Estimated post date: 2/17/26 Estimated proposal date: 4/18/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
45.	Forecast: Enhancing Global Health Security: Strengthening public health surveillance systems for disease detection and preparedness globally (CDC/GHC) CDC-RFA-JG-26-0113	This NOFO is intended to support global health security partners to develop or continue the implementation of surveillance activities that focus on protecting and improving public health globally through strategic planning, policy, strengthening surveillance capacities and systems through partnerships. These surveillance systems should build and improve regional and country capacities to detect, respond, control, and prevent infectious diseases and emerging threats; strengthen border health security; and mitigate public health events of international concern (PHEICs) or other global health issues. https://www.grants.gov/search-results-detail/360617	TBD	Estimated post date: 2/16/26 Estimated proposal date: 4/16/26
46.	Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-25-012	This NOFO is soliciting applications to participate in a consortium of Research Centers focused on designing, optimizing, evaluating, and developing broadly protective vaccines for hepatitis C virus to enable the advancement of vaccine candidates into clinical evaluation. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-25-012.html	Up to \$2 million per year, for up to 5 years	Proposal: 11/7/25
47.	Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed) (NIH Common Fund) RFA-RM-25-006	This NOFO supports small pilot projects that extend the goals of the HVP, including further validating, improving, and complementing existing and newly developed tools from the HVP program by leveraging human specimens collected from the cohorts under the program; samples from animals to promote the refinement, utilization, and translation of these tools to better serve the goals of the HVP program; expanding existing cohorts and/or biospecimen sampling sites for virome characterization; developing tools and methods to study the human virome; and defining interactions between the human virome and host. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-25-006.html	Up to \$100,000 per year, for 2 years	Proposal: 11/24/25
		MATERNAL AND PEDIATRIC HEALTH (3)		
48.	Forecast: Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents (NIH/NIMH) PAR-26-049	NIMH seeks research that helps determine the best dosing strategies when testing new psychiatric medications in children and adolescents with serious mental illnesses. This NOFO will focus on developing and refining CNS tools and models that can show how medications affect the brain in young people. These tools might include functional brain imaging methods like EEG or fMRI, as well as digital health measures or cognitive assessments. Studies are encouraged that explore how dosing impacts drug exposure and related CNS functional effects. The overall goal is to improve the safety and effectiveness of pediatric clinical trials by developing pediatric pharmacodynamic measures, to associate pharmacodynamic data with pharmacokinetic data, and to establish associated models. https://www.grants.gov/search-results-detail/360576	TBD	Estimated post date: 12/13/26 Estimated proposal date: 2/13/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MATERNAL AND PEDIATRIC HEALTH		
49.	Forecast: Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledge and Research Coordination Center (NIH/NICHD) RFA-HD-26-009	The MPRINT KRCC will accelerate safe, effective drug development and regulatory science through expanding the available knowledge, tools, and expertise in maternal and pediatric therapeutics by: (1) Developing an easily queryable curated and interoperable pharmacology knowledgebase; (2) Leveraging real-world clinical data and insights, particularly through mother-baby linkages; (3) Supporting and leveraging efficient and innovative clinical trials in pediatrics, obstetrics, and lactation; (4) Uniting multidisciplinary expertise and training the future workforce. https://www.grants.gov/search-results-detail/360584	Total funding of \$3.625 million	Estimated post date: 11/21/25 Estimated proposal date: 3/2/26
50.	Forecast: Maternal Medications and Human Milk Research Center (M2HMRC) (NIH/NICHD) RFA-HD-26-010	The M2HMRC will advance research on how maternal medications affect human milk composition and neonatal/infant health outcomes by: (1) Identifying critical knowledge gaps in medication use during pregnancy and lactation; (2) Integrating real-world evidence with chemical and bioanalytic data; (3) Developing innovative tools to improve medication safety and efficacy; and (4) Disseminating knowledge around medication use during lactation to a broad audience. The Center will collaborate with MPRINT's Knowledge and Research Coordinating Center (KRCC) to conduct cutting-edge clinical, translational, and data science research. https://www.grants.gov/search-results-detail/360585	Total funding of \$2.5 million	Estimated post date: 11/3/26 Estimated proposal date: 3/2/26
		MEDICAL COUNTERMEASURES (1)		
51.	Advancing Biodefense Readiness: On-Demand Biologics, Automated Threat Detection, and Alternative MCM Testing in High Containment (MTEC) 25-10-DTRA_Multi	This RPP is focused on advancing four medical and bioengineering technologies. Focus areas are: Biologics on Demand; Automated Clinical and/or Environmental Sampling, Sequencing, and Analysis; Alternative Methods for Testing MCMs in High Containment; and Microphysiological Alternatives for Gauging Pretreatment Immunogenicity and Efficacy (MAGPIE). https://mtec-sc.org/solicitations/25-10-dtra_multi	Dependent upon proposal and focus area	White paper: 10/28/25
		MENTAL HEALTH (2)		
52.	Forecast: Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (NIH/NIMH) PAR-26-043	Primary research objectives include 1) advancing the state of science in basic brain and behavior research to uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders, 2) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses, and/or 3) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. https://www.grants.gov/search-results-detail/360574	Up to \$2 million	Estimated post date: 2/9/26 Estimated proposal date: 6/9/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH		
53.	Optimizing Treatment Strategies for Adult Attention-Deficit Hyperactivity Disorder (ADHD) (R01 Clinical Trial Required) (NIH/NIMH) RFA-MH-26-195	NIMH seeks clinical research applications that support the development of evidence-based treatment approaches for adult ADHD that go beyond stimulant medications, utilizing nonstimulant medications, psychosocial interventions, and device-based treatments, sequentially or in combination, in situations where stimulant monotherapy is insufficiently effective, difficult to tolerate, or undesirable. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-26-195.html	Dependent upon proposal, for up to 5 years	Proposal: 11/25/25
		MICROGRAVITY RESEARCH (1)		
54.	NSF/CASIS Transport Phenomena Research at the International Space Station to Benefit Life on Earth (NSF/CASIS) NSF 25-529	The solicitation seeks to increase use of the ISS National Lab for fluid dynamics, particulate and multiphase processes, combustion and fire systems, thermal transport processes, and nanoscale interactions studies to benefit applications or industries on Earth, to promote ISS as well as new and existing facility/technology utilization. Ideal proposals will describe a commercial, civil, or academic project to achieve research or technology development objectives that will directly impact areas including: Carbon emissions and capture; Manufacturing; Medical devices and pharmaceuticals; Microfluidics and nanofluidics; and Disaster prevention and mitigation. https://new.nsf.gov/funding/opportunities/nsfcasis-transport-phenomena-research-international-space/nsf25-529/solicitation	Up to \$400,000, for up to 4 years	Feasibility Review Form: 1/12/26 Proposal: 3/4/26
		NURSING RESEARCH (1)		
55.	Community-Partnered Nursing Research Centers (P20 Clinical Trial Optional) (NIH/NINR) PAR-25-439	This NOFO supports the development of innovative research centers to foster nursing-led programs that promote community-partnered research to address persistent health challenges. https://grants.nih.gov/grants/guide/pa-files/PAR-25-439.html	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 5/7/28
		PRECISION MEDICINE (1)		
56.	Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) (ARPA-H) ARPA-H-SOL-25-122	THRIVE aims to make personalized and affordable cures available to all rare disease patients. The program intends to develop pioneering integrated platform technologies to accelerate precision genetic medicines (PGMs) and provide single-intervention precision treatments to slow, reverse, or prevent chronic diseases at the genetic level. THRIVE is designed to optimize affordability, scalability, and sustainability of lifesaving PGMs for patients through existing regional treatment centers and virtual clinics. https://sam.gov/workspace/contract/opp/c35d47c1cc4d40bob496d2d62d894495/view	Dependent upon proposal and award mechanism	Solution Summary: 10/31/25 Proposal: 12/19/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		RARE DISEASES (1)		
57.	Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) (NIH/NCATS/NICHD) PAR-25-450	This NOFO invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics toward clinical trials and to increase their likelihood of success. https://grants.nih.gov/grants/guide/pa-files/PA-25-450.html	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 7/20/28
		REPRODUCTIVE HEALTH (2)		
58.	Forecast: Biological Testing Facility for Contraception & Reproductive Health (NIH/NICHD) PAR-26-071	This NOFO will solicit applications for access to a state-of-the-art Biological Testing Facility (BTF) for advancing both contraceptive and reproductive health-related product development. There is a critical need for fertility regulation methods that fit the needs of women and men throughout their reproductive lives, and it is also essential to support the development of new therapies related to reproductive health. https://www.grants.gov/search-results-detail/360583	TBD	Estimated post date: 10/6/25 Estimated proposal date: 1/5/26
59.	Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional) (NIH/NICHD) RFA-HD-26-001	This NOFO supports and facilitates multidisciplinary research approaches for the development or improvement of technologies, including drugs, devices, products, or clinical practices designed to improve fertility outcomes in patients dealing with infertility, particularly in the context of Assisted Reproductive Technologies (ART). https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-26-001.html	Up to \$300,000 per year, for up to 2 years (R61) Up to \$471,000 per year, for up to 3 years (R33)	Proposal: 11/21/25
		SMALL BUSINESS DEVELOPMENT (2)		
60.	DSO Pitch Day Solicitation (DoD/DARPA) DARPA-PA-26-01	DARPA DSO will host a Pitch Day for engagement with prospective proposers and to catalyze future efforts in selected Technical Thrust Areas. In order to be selected, proposals must investigate innovative new scientific or research approaches that enable revolutionary advances. The goals of the DSO Pitch Day are to: 1. fund proposals for targeted, short-term efforts with the potential to grow into groundbreaking new DARPA programs, and 2. employ an acquisition strategy to encourage participation by new and first-time or non-traditional proposers. https://sam.gov/workspace/contract/opp/8ce78d0be9514a158e0dc4ea2f3ebd6b/view https://sam.gov/opp/c3f0bedbf22c4e2daf5bbo713f4ce4a/view	Up to \$400,000, for 9 months	Abstract: 10/27/25 Pitch Day Package: 12/16/25 Pitch Day: 1/14/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT		
61.	DoD SBIR 25.4 Release 12 (DoD/CBD) DoD SBIR 2025.4	Topics include: Shelf-Stable Nucleic Acid Synthesis Reagents for Field-Deployable Diagnostics; OPEN TOPIC - Expeditionary Biologics-on-Demand (BOND); Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE); Complex Geometries for Extended Wear Respirators Towards Regenerable Particulate Matter Protection; Novel Sampling Tickets for Surface Enhanced Raman Spectroscopy (SERS) of Chemical and Biological (CB) Threat Materials; and Far Forward Manufacturing of CBRN Sensors. https://www.dodsbirsttr.mil/topics-app/	Up to \$209,575, for up to 6 months (Phase I) Up to \$1.397 million, for up to 2 years (D2P2)	Proposal: 11/5/25
		SUBSTANCE USE DISORDER (5)		
62.	Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) (NIH/NIDA) PAR-25-446	This NOFO seeks grant applications to support research on the discovery and development of interventions to prevent and/or treat SUDs and overdose, including interventions to treat co-morbid SUDs. This includes preclinical and clinical research studies that will have high impact and quickly yield the necessary results to advance candidate interventions closer to regulatory approval or clinical adoption. https://grants.nih.gov/grants/guide/pa-files/PAR-25-446.html	Up to \$3 million per year, for up to 5 years	Multiple deadlines; NOFO open through 8/21/28
63.	Forecast: NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (NIH/NIDA) PAR-26-051	NIDA will provide access to biospecimens from the Adolescent Brain Cognitive Development (ABCD) Study, the HEALthy Brain and Child Development (HBDC) Study, and the Population Assessment of Tobacco and Health (PATH) Study to conduct research consistent with study objectives that will maximize the scientific utility of these samples. Research proposals should expand the knowledge gained from these studies and advance our understanding the multiple genetic and environmental factors that affect health and disease over the course of a lifetime. https://www.grants.gov/search-results-detail/360554	TBD	Estimated post date: 5/1/26 Estimated proposal date: 9/8/26
64.	Forecast: Science Track Award for Research Transition (START) Program (NIH/NIDA) PAS-26-035	NIDA seeks to advance its mission by providing seed funding for projects that build expertise and enable research at the intersection of substance use research and one or more of the following fields: Discovery and development of new chemical entities or biologics to advance therapeutic interventions for SUDs and drug dependence; Development and application of brain imaging tools or brain imaging methods; Application of innovative neurocognitive and behavioral science tools or paradigms; Application of advanced data science techniques and innovative computational methods; Research that can lead to advancing basic, clinical, translational, epidemiological, or intervention science regarding substance use and HIV/AIDS https://www.grants.gov/search-results-detail/360553	Up to \$100,000	Estimated post date: 12/15/26 Estimated proposal date: 2/16/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
65.	Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for SUDs (U54 - Clinical Trials Not Allowed) (NIH/NIDA) RFA-DA-26-020	This NOFO invites applications to establish and lead a Center dedicated to accelerating drug development for SUDs through re-purposing and repositioning strategies. The Center's core mission will be to serve academic and biotech investigators by providing expert guidance, shared resources, and tailored support across all stages of product development. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-020.html	Dependent upon proposal, for up to 5 years	Proposal: 1/28/26
66.	Forecast: Neural Ensembles & Used Substances (NExUS) Collaboratory : Building a Multimodal Inventory of Cell Ensembles Encoding the Effects of Addictive Substances (NIH/NIDA) RFA-DA-27-010	NExUS is an effort to build a knowledgebase of the neural cell populations and computations altered by substance-associated experiences, and underlying neurobehavioral states characteristic of addiction, or protective against it. https://www.grants.gov/search-results-detail/360562	Up to \$700,000	Estimated post date: 3/2/26 Estimated proposal date: 6/2/26
		THERAPEUTICS (2)		
67.	Forecast: NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) (NIH/NEI) PAR-26-073	The purpose of NEI's Translational Research program is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system. https://www.grants.gov/search-results-detail/360545	TBD	Estimated post date: 11/3/26 Estimated proposal date: 2/16/26
68.	Forecast: Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed) (NIH/NCATS) RFA-TR-25-016	This NOFO will solicit applications that will develop, validate and demonstrate the utility of advanced 3-D tissue models for testing the efficacy of various therapeutic modalities, including small molecules and biologics and accelerate the discovery and development of new therapeutics across different diseases. The initiative will develop advanced 3-D drug screening models adaptable to high throughput assays. These non-animal models are expected to mimic structural, biochemical and mechanical properties of tissue that are representative of a drug's behavior in a body, resulting in improved predictive accuracy. https://www.grants.gov/search-results-detail/360666	Total funding of \$1.6 million	Estimated post date: 1/16/26 Estimated proposal date: 4/15/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		TOXIC EXPOSURES (1)		
69.	Evaluating and Conducting Computational and Alternative Toxicological Methods for NIEHS (NIH/NIEHS) 75N96025R00004	The contractor will support NIEHS by conducting and evaluating toxicological testing using computational and/or alternative approaches, also referred to New Approach Methodologies (NAMs). The areas of focus for the research include but are not limited to population variability, susceptibility, developmental neurotoxicity, carcinogenicity, ecotoxicity, acute toxicity, etc. https://sam.gov/workspace/contract/opp/f267edcc4cca49f6a9d82f49917b4009/view	Dependent upon contract	Proposal: 11/3/25
		UROLOGIC RESEARCH (1)		
70.	Forecast: George M. O'Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional) (NIH/NIDDK) RFA-DK-27-128	The Urology Cooperative Research Centers foster impactful, multi-disciplinary research through diverse collaborations within and outside the Centers and serve as a national resource for the urology research community. https://www.grants.gov/search-results-detail/360551	Total funding of \$5.3 million	Estimated post date: 4/1/26 Estimated proposal date: 7/1/26



Recurring Opportunities

October 9, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
71.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. https://sam.gov/opp/c575f73500844322be760e0d98c233ac/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
72.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/opp/173be613d10249d8b0096c649e5203b8/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
73.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations. https://sam.gov/opp/d85f2223a88442f3ba6eedf9a0629775/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
74.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/opp/ca0ae33ab9544686b47788025c67cca2/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
75.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care. https://sam.gov/opp/4caa8d320fb24050b389fe721296a13d/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
76.	AFRL/RX Functional Materials Open BAA FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The Biomaterials Materials and Processes (BM&P) Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio- functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing. https://sam.gov/opp/2fadbd41c2700409c993a8c308c6f5120/view	Dependent upon proposal and award mechanism	White paper: 10/28/28
77.	Research Interests of the Air Force Office of Scientific Research FA9550-25-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological nature by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well- understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility. https://www.grants.gov/search-results-detail/359050	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
78.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY (9)		
79.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
80.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
81.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
82.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
83.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is here . https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
84.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
85.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
86.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center W911QY-25-R-0023	The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding & Equipment; Soldier Protection & Survivability; Modeling & Simulation; Human Performance & Biomechanics; Expeditionary Maneuver Support; Aerial Delivery; and Simulation & Training Technology. https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
87.	Medical CDID BAA MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics (medical resupply). https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-c0bea38cd0b1	Dependent upon proposal	White papers accepted through 12/31/2030
88.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/fca6a4b42ff94fd5892fdae9799941f/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<u>BARDA (2)</u>		
89.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/d832248e72e14c3c8cee96ee3c8b2170/view	Dependent upon proposal	Proposal: 9/25/28
90.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. https://sam.gov/opp/6684d4a2734047d58d6cbf7e50bdd00a/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		<u>DARPA (3)</u>		
91.	Expedited Research Innovation System (ERIS) DARPA-PS-25-05	DARPA seeks to obtain solutions or capabilities that deliver breakthrough technological advancements that are new as of the date of submission; or technologies, processes, research or methods. Topics include: Advanced technologies for defense against potential chemical and biological threats, human-made or naturally occurring; Advanced technologies for the improved resilience of US operations; and Development of groundbreaking methods and metrology for complex, emergent, and adaptive systems. https://sam.gov/workspace/contract/opp/fabda3a3d150457d97068977672ec750/view	Dependent upon proposal and award mechanism	Proposal: 5/30/26
92.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Combat Casualty Care; Human Performance; Materials, Sensors, Processing; Agricultural and Environmental; Security, Safety, and Surveillance; and Biomedical and Biodefense. https://sam.gov/workspace/contract/opp/8d403582edfd409795560247e8d229b7/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/30/26
93.	Defense Sciences Office, Office-wide HR001125S0013	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. https://sam.gov/opp/c3f0bedbf22c4e2daf5bbo713f4ce4a/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/2/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (4)		
94.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E : • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
95.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
96.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
97.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
98.	FY 2026 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003600	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/360678	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/26
		NATIONAL SCIENCE FOUNDATION (2)		
99.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 24-579	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View the full list of topics . https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-0/nsf24-579/solicitation	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis through 11/5/25.
100.	NSF Small Business Innovation Research / Small Business Technology Transfer Fast-Track Pilot Programs (SBIR-STTR Fast-Track) NSF 24-582	The NSF SBIR/STTR Fast-Track programs provide non-dilutive, fixed amount cooperative agreements for the development of a broad range of technologies based on discoveries in science and engineering with the potential for societal and economic impacts. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-1/nsf24-582/solicitation	Up to \$1,555,000, for up to 3 years	Project pitches accepted on a rolling basis through 11/5/25. Proposal: 11/5/25
		NAVY (2)		
101.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://sam.gov/workspace/contract/opp/oefe2fde0926428f8ecc073f3fc7b5d9/view	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NAVY		
102.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/workspace/contract/opp/f85a428ac9ac46c4a3278e11394c18d9/view	Dependent upon proposal and award mechanism	White papers accepted through 3/31/26
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
103.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (4)		
104.	Forecast: Phased Large Awards for Comparative Effectiveness Research – Cycle 1 2026	PCORI is interested in research that aims to fill pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader health and healthcare community make informed decisions about their health care and health outcomes. Applicants to the Cycle 1 2026 PLACER PFA may select up to three Topic Themes ; or Other. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-1-2026	Up to \$22 million, for up to 6.5 years	System opens: 12/2/25 Letter of intent: 1/6/26 Proposal: 5/5/26
105.	Forecast: Broad Pragmatic Studies Funding Announcement - Cycle 1 2026	PCORI is interested in research that fills pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader healthcare community make informed decisions about their health care and health outcomes. Applicants for the 2026 BPS PFA may select up to three of PCORI's Topic Themes ; or "Other." Cycle 1 SAEs include: Addressing Obesity; Treatments and Strategies To Address Menopausal Symptoms; and Improving Care Delivery for Individuals With Intellectual and Developmental Disabilities (IDD). https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-1-2026	Up to \$12 million, for up to 5 years Dependent upon award mechanism Dependent upon award mechanism	System opens: 12/2/25 Letter of intent: 1/6/26 Proposal: 5/5/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
106.	Forecast: Advancing the Science of Engagement in Research PCORI Funding Announcement -- Cycle 1 2025	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research; Techniques that lead to effective engagement in research; and How effective engagement techniques should be modified and resourced for different contexts, settings, and communities. It will solicit applications that focus on: Development and validation of measures to capture structure/context, process and outcomes of engagement, for both stakeholders and investigators; and Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement in research and how effectiveness varies by context. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-1-2026	Up to \$1.5 million, for up to 3 years	System opens: 12/2/25 Letter of intent: 1/6/26 Proposal: 5/5/26
107.	Forecast: Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 1 2026	PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by CER studies. For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in CER; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-1-2026	Up to \$750,000, for up to 3 years	System opens: 12/2/25 Letter of intent: 1/6/26 Proposal: 5/5/26





Terms

AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

GBG Acronyms

Updated Monthly

October 9, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

NIH Institutes and Centers

CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIHES: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Join the private GBG Zoom Meeting:

<https://uso6web.zoom.us/j/82427540990?pwd=M8rNBzb8KbjpoKazNza5K9QeX1U1Cm.1>

Meeting ID: 824 2754 0990

Passcode: 340360

